CANADIAN CONTRIBUTION TO NCI INTERGROUP CANCER TRIALS

此应用程序的目标是增强改进 通过合作临床试验治疗癌症患者。 随机临床试验提供了关于 不同形式治疗的有效性；因此，国家 癌症研究所(NCI)资助了致力于 开展和开展这些研究。现在很明显，尽管 这些小组经常可以独立地进行重要的审判，在许多情况下 他们之间需要案例合作来回答关键问题 要快点。因此，制定和实施的正式机制 已经实施了“组间”试验，并进行了一些此类研究 已经完工了。 加拿大国家癌症研究所，一个由捐款资助的机构 加拿大癌症协会，支持一个临床试验小组(NCIC Ctg(CTG：行情)，其职能和结构类似于美国集团.像美国一样 NCIC CTG进行了许多自己的研究，并已 对现行标准的制定做出了重要贡献 关心。NCIC CTG还积极参与了组间试验， 作为一个参与和“牵头”小组。 此应用程序的直接目的是寻求支持 继续并加强NCIC CTG在美国集团间的参与 有以下具体目标的研究：1.贡献患者 注册、数据管理资源和高质量数据，以 由NCI赞助的小组间试验；2.为 NCI组间试验的开发、设计和实施； 为一些NCI集团提供领导和协调资源 审判。 如果没有在本申请中寻求的资金，NCIC CTG可以在 最好的，为重要的研究工作做出有限的贡献 以组间试验为代表。有了它，集团可以在 确定要解决的问题并确保这些问题得到回答 又快又准。

The goal of this application is to enhance the process of improving the treatment of cancer patients through cooperative clinical trials. Randomized clinical trials provide the best evidence concerning the effectiveness of different forms of therapy; consequently the National Cancer Institute (NCI) has funded clinical trials groups dedicated to developing and conducting these studies. It is now clear that, although these groups can often undertake important trials independently, in many cases cooperation among them is needed to answer key questions expeditiously. Thus, formal mechanisms for developing and conducting "intergroup" trials have been implemented and a number of such studies have been completed. The National Cancer Institute of Canada, an agency funded by donations to the Canadian Cancer Society, supports a clinical trials group (NCIC CTG) which has functions and a structure similar to US groups. Like US groups, the NCIC CTG has conducted numerous studies of its own and has made important contributions to the development of current standards of care. The NCIC CTG has also been active in intergroup trials, both as a participating and as a "lead" group. The immediate purpose of this application is to seek support for continued and enhanced participation of the NCIC CTG in US intergroup studies with the following specific aims: 1. To contribute patient enrolment, data management resources, and high quality data to intergroup trials sponsored by NCI; 2. To provide scientific input into the development design and conduct of NCI intergroup trials; and 3. To provide leadership and coordination resources for some NCI intergroup trials. Without the funding sought in this application, the NCIC CTG can, at best, make a limited contribution to the important research effort represented by intergroup trials. With it, the Group can help both in defining the questions to be addressed and in ensuring they are answered quickly and correctly.